Oxygen Biotherapeutics, Inc. Study Reveals Dermacyte(R) Concentrate's Potential to Relieve Histamine-Induced Pruritus in Healthy Patients

MORRISVILLE, N.C., May 31, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) announced today that data from its clinical study to determine the efficacy of Dermacyte® in relieving histamine-induced pruritus show that Dermacyte elicited a significantly larger reduction in Visual Analogue Scale scores following a standard histamine skin prick compared to placebo.

Back to news